Biomedical Research Education & Training
Faculty Member

Penson, David F, MD, MPH
Director Center for Surgical Quality and Outcomes Research
Professor of Urologic Surgery
Paul V. Hamilton, M.D. and Virginia E. Howd Chair in Urologic Oncology
Professor of Medicine

Lab Url: N/A

Phone Number: 615-343-1529

Email Address: david.penson@vanderbilt.edu

Penson, David's picture
Academic history
BA, University of Pennsylvania, Philadelphia, PA
MD, Boston University, Boston, MA
MPH, Yale University, New Haven, CT

Office Address   Mailing Address

2525 West End Avenue, Suite 1200

37203-1738


Clinical Research Keywords
health services research, clinical epidemiology, pharmacoeconomics, patient-reported outcomes, surgery

Patient Care Specialty
prostate cancer, bladder cancer, benign prostate disease, erectile dysfunction

Clinical Research Description
My primary research interest has been in using population-based cohorts and assessing patient-reported outcomes in conditions treated with surgical procedures, specifically prostate cancer. My additional interests include (but are not limited to) cost-effectiveness analyses, exploring disparities in access and quality of care across numerous surgical conditions. I also maintain a focus on improving clinical decision-making.

Publications
Anderson, CB, Morgan, TM, Kappa, S, Moore, D, Clark, PE, Davis, R, Penson, DF, Barocas, DA, Smith, JA, Cookson, MS, Chang, SS. Ureteroenteric anastomotic strictures after radical cystectomy-does operative approach matter. J Urol, 189(2), 541-7, 2013

Anderson, CB, Penson, DF, Ni, S, Makarov, DV, Barocas, DA. Centralization of radical prostatectomy in the United States. J Urol, 189(2), 500-6, 2013

Barocas, DA, Grubb, R, Black, A, Penson, DF, Fowke, JH, Andriole, G, Crawford, ED. Association between race and follow-up diagnostic care after a positive prostate cancer screening test in the Prostate, Lung, Colorectal, and Ovarian cancer screening trial. Cancer, 119(12), 2223-9, 2013

Kaffenberger, SD, Keegan, KA, Bansal, NK, Morgan, TM, Tang, DH, Barocas, DA, Penson, DF, Davis, R, Clark, PE, Chang, SS, Cookson, MS, Herrell, SD, Smith, JA. Salvage robotic assisted laparoscopic radical prostatectomy: a single institution, 5-year experience. J Urol, 189(2), 507-13, 2013

Penson, DF. Editorial comment. J Urol, 190(2), 398, 2013

Penson, DF. Post-prostatectomy Incontinence and Pelvic Floor Muscle Training: A Defining Problem. Eur Urol, 2013

Penson, DF. Time to raise the bar in localised prostate cancer. BJU Int, 112(3), 278, 2013

Penson, DF. Capsule Commentary on Shahinian et al.: Patterns of Bone Mineral Density Testing in Men Receiving Androgen Deprivation for Prostate Cancer. J Gen Intern Med, 2013

Resnick, MJ, Guzzo, TJ, Cowan, JE, Knight, SJ, Carroll, PR, Penson, DF. Factors associated with satisfaction with prostate cancer care: results from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). BJU Int, 111(2), 213-20, 2013

Resnick, MJ, Koyama, T, Fan, KH, Albertsen, PC, Goodman, M, Hamilton, AS, Hoffman, RM, Potosky, AL, Stanford, JL, Stroup, AM, Van Horn, RL, Penson, DF. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med, 368(5), 436-45, 2013

Reynolds, WS, Dmochowski, RR, Lai, J, Saigal, C, Penson, DF, , . Patterns and predictors of urodynamics use in the United States. J Urol, 189(5), 1791-6, 2013

Reynolds, WS, Gold, KP, Ni, S, Kaufman, MR, Dmochowski, RR, Penson, DF. Immediate effects of the initial FDA notification on the use of surgical mesh for pelvic organ prolapse surgery in medicare beneficiaries. Neurourol Urodyn, 32(4), 330-5, 2013

Barocas, DA, Gray, DT, Fowke, JH, Mercaldo, ND, Blume, JD, Chang, SS, Cookson, MS, Smith, JA, Penson, DF. Racial variation in the quality of surgical care for prostate cancer. J Urol, 188(4), 1279-85, 2012

Fowke, JH, Motley, SS, Concepcion, RS, Penson, DF, Barocas, DA. Obesity, body composition, and prostate cancer. BMC Cancer, 12, 23, 2012 PMCID:3292483

Kavitt, RT, Penson, DF, Vaezi, MF. Eosinophilic esophagitis: dilate or medicate? A cost analysis model of the choice of initial therapy. Dis Esophagus, 2012

Keegan, KA, Penson, DF. The patient protection and affordable care act: The impact on urologic cancer care. Urol Oncol, 2012

Makarov, DV, Desai, RA, Yu, JB, Sharma, R, Abraham, N, Albertsen, PC, Penson, DF, Gross, CP. The population level prevalence and correlates of appropriate and inappropriate imaging to stage incident prostate cancer in the medicare population. J Urol, 187(1), 97-102, 2012 PMCID:3292483

Morgan, TM, Barocas, DA, Keegan, KA, Cookson, MS, Chang, SS, Ni, S, Clark, PE, Smith, JA, Penson, DF. Volume outcomes of cystectomy--is it the surgeon or the setting. J Urol, 188(6), 2139-44, 2012

Morgan, TM, Barocas, DA, Penson, DF, Chang, SS, Ni, S, Clark, PE, Smith, JA, Cookson, MS. Lymph node yield at radical cystectomy predicts mortality in node-negative and not node-positive patients. Urology, 80(3), 632-40, 2012

Patel, SG, Penson, DF, Pabla, B, Clark, PE, Cookson, MS, Chang, SS, Herrell, SD, Smith, JA, Barocas, DA. National trends in the use of partial nephrectomy: a rising tide that has not lifted all boats. J Urol, 187(3), 816-21, 2012 PMCID:3292483

Penson, DF. Re: Satisfaction profiles in men using intracavernosal injection therapy. J Urol, 187(1), 245-6, 2012 PMCID:3292483

Penson, DF. Re: today''s ''meaningful use'' standard for medication orders by hospitals may save few lives; later stages may do more. J Urol, 187(2), 646, 2012 PMCID:3292483

Penson, DF. Re: higher fees paid to us physicians drive higher spending for physician services compared to other countries. J Urol, 187(2), 647-8, 2012 PMCID:3292483

Penson, DF. Re: US physician practices versus Canadians: spending nearly four times as much money interacting with payers. J Urol, 187(2), 648, 2012 PMCID:3292483

Penson, DF. Re: How Well Informed are Women Who Undergo Urodynamic Testing. J Urol, 187(3), 965, 2012

Penson, DF. Re: physician documentation of fluoroscopy time in voiding cystourethrography reports correlates with lower fluoroscopy times: a surrogate marker of patient radiation exposure. J Urol, 187(3), 965-6, 2012

Penson, DF. Re: Urologist Compliance With AUA Best Practice Guidelines for Benign Prostatic Hyperplasia in Medicare Population. J Urol, 187(3), 966-7, 2012

Penson, DF. Editorial Comments. J Urol, 2012

Penson, DF. Re: Fifteen-year trend in the use of male reproductive surgery: analysis of the healthcare cost and utilization project data. J Urol, 187(1), 246, 2012 PMCID:3292483

Penson, DF. Factors influencing patients'' acceptance and adherence to active surveillance. J Natl Cancer Inst Monogr, 2012(45), 207-12, 2012

Resnick, MJ, Penson, DF. Quality of life with advanced metastatic prostate cancer. Urol Clin North Am, 39(4), 505-15, 2012

Wein, AJ, Penson, DF. Re: What patients think: patient-reported outcomes of retropubic versus trans-obturator mid-urethral slings for urodynamic stress incontinence--a multi-centre randomised controlled trial. J Urol, 187(1), 203-5, 2012

Wein, AJ, Penson, DF. Re: Transobturator TVT-O versus retropubic TVT: results of a multicenter randomized controlled trial at 24 months follow-up. J Urol, 187(1), 203-4, 2012

Wein, AJ, Penson, DF. Re: Retropubic versus transobturator midurethral slings for stress incontinence. J Urol, 187(1), 202-4, 2012 PMCID:3292483

Barocas, DA, Motley, S, Cookson, MS, Chang, SS, Penson, DF, Dai, Q, Milne, G, Roberts, LJ, Morrow, J, Concepcion, RS, Smith, JA, Fowke, JH. Oxidative Stress Measured by Urine F2-Isoprostane Level is Associated With Prostate Cancer. J Urol, 2011

Birkhahn, M, Penson, DF, Cai, J, Groshen, S, Stein, JP, Lieskovsky, G, Skinner, DG, Cote, RJ. Long-term outcome in patients with a Gleason score a??6 prostate cancer treated by radical prostatectomy. BJU Int, 2011

Davies, JD, Aghazadeh, MA, Phillips, S, Salem, S, Chang, SS, Clark, PE, Cookson, MS, Davis, R, Herrell, SD, Penson, DF, Smith, JA, Barocas, DA. Prostate size as a predictor of Gleason score upgrading in patients with low risk prostate cancer. J Urol, 186(6), 2221-7, 2011 PMCID:3292483

Epplein, M, Zheng, Y, Zheng, W, Chen, Z, Gu, K, Penson, D, Lu, W, Shu, XO. Quality of life after breast cancer diagnosis and survival. J Clin Oncol, 29(4), 406-12, 2011

Fowke, JH, Munro, H, Signorello, LB, Blot, WJ, Penson, DF, , . Association between socioeconomic status (SES) and lower urinary tract symptom (LUTS) severity among black and white men. J Gen Intern Med, 26(11), 1305-10, 2011 PMCID:3292483

Makarov, DV, Yu, JB, Desai, RA, Penson, DF, Gross, CP. The association between diffusion of the surgical robot and radical prostatectomy rates. Med Care, 49(4), 333-9, 2011

Maripuri, S, Penson, DF, Ikizler, TA, Cavanaugh, KL. Outpatient versus inpatient observation after percutaneous native kidney biopsy: a cost minimization study. Am J Nephrol, 34(1), 64-70, 2011 PMCID:3123742

McVary, KT, Roehrborn, CG, Avins, AL, Barry, MJ, Bruskewitz, RC, Donnell, RF, Foster, HE, Gonzalez, CM, Kaplan, SA, Penson, DF, Ulchaker, JC, Wei, JT. Update on AUA Guideline on the Management of Benign Prostatic Hyperplasia. J Urol, 185(5), 1793-803, 2011

Morgan, TM, Barocas, DA, Chang, SS, Phillips, SE, Salem, S, Clark, PE, Penson, DF, Smith, JA, Cookson, MS. The relationship between perioperative blood transfusion and overall mortality in patients undergoing radical cystectomy for bladder cancer. Urol Oncol, 2011 PMCID:3292483

Morgan, TM, Keegan, KA, Barocas, DA, Ruhotina, N, Phillips, SE, Chang, SS, Penson, DF, Clark, PE, Smith, JA, Cookson, MS. Predicting the probability of 90-day survival of elderly patients with bladder cancer treated with radical cystectomy. J Urol, 186(3), 829-34, 2011 PMCID:3292483

Padmanabhan, P, Scarpero, HM, Milam, DF, Dmochowski, RR, Penson, DF. Five-year cost analysis of intra-detrusor injection of botulinum toxin type A and augmentation cystoplasty for refractory neurogenic detrusor overactivity. World J Urol, 29(1), 51-7, 2011

Penson, DF. Treatment for postprostatectomy incontinence: is this as good as it gets. JAMA, 305(2), 197-8, 2011

Penson, DF. Re: Treatment Outcomes and Resource Use of Patients With Neurogenic Detrusor Overactivity Receiving Botulinum Toxin A (BOTOX) Therapy in Germany. J Urol, 185(4), 1383-4, 2011 PMCID:3292483

Penson, DF. Re: can pelvic floor muscle training reverse pelvic organ prolapse and reduce prolapse symptoms? An assessor-blinded, randomized, controlled trial. J Urol, 185(4), 1383, 2011 PMCID:3292483

Penson, DF. Re: Complementary and Alternative Medicine (CAM) Use in Women With Pelvic Floor Disorders: A Cohort Study. J Urol, 185(4), 1382-3, 2011 PMCID:3292483

Penson, DF. Re: Assessment of quality of cancer-related follow-up care from the cancer survivor''s perspective. J Urol, 186(6), 2349, 2011 PMCID:3292483

Penson, DF. Re: Validating the patient safety indicators in the Veterans Health Administration: are they ready for prime time. J Urol, 186(6), 2347-8, 2011 PMCID:3292483

Penson, DF, Lange, PH. Systemic therapy and the urologic oncologist: a unique opportunity for the specialty to provide comprehensive care that ultimately benefits the patient. Urol Oncol, 30(4 Suppl), S2-4, 2011

Penson, DF, Munro, HM, Signorello, LB, Blot, WJ, Fowke, JH, , . Obesity, physical activity and lower urinary tract symptoms: results from the Southern Community Cohort Study. J Urol, 186(6), 2316-22, 2011 PMCID:3292483

Reynolds, WS, Dmochowski, RR, Penson, DF. Epidemiology of stress urinary incontinence in women. Curr Urol Rep, 12(5), 370-6, 2011 PMCID:3292483

Wessells, H, Penson, DF, Cleary, P, Rutledge, BN, Lachin, JM, McVary, KT, Schade, DS, Sarma, AV, , . Effect of intensive glycemic therapy on erectile function in men with type 1 diabetes. J Urol, 185(5), 1828-34, 2011

Zeliadt, SB, Penson, DF, Moinpour, CM, Blough, DK, Fedorenko, CR, Hall, IJ, Smith, JL, Ekwueme, DU, Thompson, IM, Keane, TE, Ramsey, SD. Provider and partner interactions in the treatment decision-making process for newly diagnosed localized prostate cancer. BJU Int, 2011

Barocas, DA, Penson, DF. Racial variation in the pattern and quality of care for prostate cancer in the USA: mind the gap. BJU Int, 106(3), 322-8, 2010

Hadley, J, Yabroff, KR, Barrett, MJ, Penson, DF, Saigal, CS, Potosky, AL. Comparative Effectiveness of Prostate Cancer Treatments: Evaluating Statistical Adjustments for Confounding in Observational Data. J Natl Cancer Inst, 2010

Hamilton, AS, Albertsen, PC, Johnson, TK, Hoffman, R, Morrell, D, Deapen, D, Penson, DF. Trends in the treatment of localized prostate cancer using supplemented cancer registry data. BJU Int, 2010

Huang, GJ, Sadetsky, N, Penson, DF. Health related quality of life for men treated for localized prostate cancer with long-term followup. J Urol, 183(6), 2206-12, 2010

Kantoff, PW, Higano, CS, Shore, ND, Berger, ER, Small, EJ, Penson, DF, Redfern, CH, Ferrari, AC, Dreicer, R, Sims, RB, Xu, Y, Frohlich, MW, Schellhammer, PF, , . Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med, 363(5), 411-22, 2010

Makarov, DV, Loeb, S, Landman, AB, Nielsen, ME, Gross, CP, Leslie, DL, Penson, DF, Desai, RA. Regional variation in total cost per radical prostatectomy in the healthcare cost and utilization project nationwide inpatient sample database. J Urol, 183(4), 1504-9, 2010

Moses, KA, Paciorek, AT, Penson, DF, Carroll, PR, Master, VA. Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE. J Clin Oncol, 28(6), 1069-74, 2010

Ramsey, SD, Zeliadt, SB, Arora, NK, Blough, DK, Penson, DF, Oakley-Girvan, I, Hamilton, AS, Van Den Eeden, SK, Fedorenko, CR, Potosky, AL. Unanticipated and Underappreciated Outcomes During Management of Local Stage Prostate Cancer: A Prospective Survey. J Urol, 2010

Ramsey, SD, Zeliadt, SB, Fedorenko, CR, Blough, DK, Moinpour, CM, Hall, IJ, Smith, JL, Ekwueme, DU, Fairweather, ME, Thompson, IM, Keane, TE, Penson, DF. Patient preferences and urologist recommendations among local-stage prostate cancer patients who present for initial consultation and second opinions. World J Urol, 2010

Stimson, CJ, Dmochowski, R, Penson, DF. Health care reform 2010: a fresh view on tort reform. J Urol, 184(5), 1840-6, 2010

Thong, MS, Van De Poll-Franse, L, Hoffman, RM, Albertsen, PC, Hamilton, AS, Stanford, JL, Penson, DF. Diabetes mellitus and health-related quality of life in prostate cancer: 5-year results from the Prostate Cancer Outcomes Study. BJU Int, 2010

Zeliadt, SB, Moinpour, CM, Blough, DK, Penson, DF, Hall, IJ, Smith, JL, Ekwueme, DU, Thompson, IM, Keane, TE, Ramsey, SD. Preliminary treatment considerations among men with newly diagnosed prostate cancer. Am J Manag Care, 16(5), e121-30, 2010

Bruins, HM, Huang, GJ, Cai, J, Skinner, DG, Stein, JP, Penson, DF. Clinical outcomes and recurrence predictors of lymph node positive urothelial cancer after cystectomy. J Urol, 182(5), 2182-7, 2009

Makarov, DV, Penson, DF. Prostate cancer: quality of life after radiation and androgen deprivation. Nat Rev Urol, 6(9), 477-8, 2009

Nichol, MB, Knight, TK, Wu, J, Barron, R, Penson, DF. Evaluating use patterns of and adherence to medications for benign prostatic hyperplasia. J Urol, 181(5), 2214-21; discussion 2221-2, 2009

Penson, DF. Active surveillance: not your father''s watchful waiting. Oncology (Williston Park), 23(11), 980, 982, 2009

Penson, DF, Wessells, H, Cleary, P, Rutledge, BN, , . Sexual dysfunction and symptom impact in men with long-standing type 1 diabetes in the DCCT/EDIC cohort. J Sex Med, 6(7), 1969-78, 2009

Ramsey, SD, Zeliadt, SB, Arora, NK, Potosky, AL, Blough, DK, Hamilton, AS, Van Den Eeden, SK, Oakley-Girvan, I, Penson, DF. Access to information sources and treatment considerations among men with local stage prostate cancer. Urology, 74(3), 509-15, 2009 PMCID:2748115

Stein, JP, Penson, DF, Lee, C, Cai, J, Miranda, G, Skinner, DG. Long-term oncological outcomes in women undergoing radical cystectomy and orthotopic diversion for bladder cancer. J Urol, 181(5), 2052-8; discussion 2058-9, 2009

Zeliadt, SB, Ramsey, SD, Van Den Eeden, SK, Hamilton, AS, Oakley-Girvan, I, Penson, DF, Fairweather, ME, Arora, NK, Potosky, AL. Patient Recruitment Methods to Evaluate Treatment Decision Making for Localized Prostate Cancer. Am J Clin Oncol, 2009

Etzioni, R, Gulati, R, Falcon, S, Penson, DF. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach. Med Decis Making, 28(3), 323-31, 2008

Etzioni, R, Tsodikov, A, Mariotto, A, Szabo, A, Falcon, S, Wegelin, J, DiTommaso, D, Karnofski, K, Gulati, R, Penson, DF, Feuer, E. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control, 19(2), 175-81, 2008

Huang, GJ, Hamilton, AS, Lo, M, Stein, JP, Penson, DF. Predictors of intravesical therapy for nonmuscle invasive bladder cancer: results from the surveillance, epidemiology and end results program 2003 patterns of care project. J Urol, 180(2), 520-4; discussion 524, 2008

Huang, GJ, Penson, DF. Internet health resources and the cancer patient. Cancer Invest, 26(2), 202-7, 2008

Lloyd, A, Penson, D, Dewilde, S, Kleinman, L. Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer. Prostate Cancer Prostatic Dis, 11(2), 153-9, 2008

Penson, DF, McLerran, D, Feng, Z, Li, L, Albertsen, PC, Gilliland, FD, Hamilton, A, Hoffman, RM, Stephenson, RA, Potosky, AL, Stanford, JL. 5-year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study. J Urol, 179(5 Suppl), S40-4, 2008

Penson, DF, Rossignol, M, Sartor, AO, Scardino, PT, Abenhaim, LL. Prostate cancer: epidemiology and health-related quality of life. Urology, 72(6 Suppl), S3-11, 2008

Stein, JP, Penson, DF. Invasive T1 bladder cancer: indications and rationale for radical cystectomy. BJU Int, 102(3), 270-5, 2008

Stein, JP, Penson, DF. The invasive T1 bladder tumor: contemporary issues and rationale for radical cystectomy. Curr Urol Rep, 9(3), 179-81, 2008

Albertsen, PC, Hanley, JA, Penson, DF, Barrows, G, Fine, J. 13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort. J Urol, 177(3), 932-6, 2007

Gonzalez, CM, Penson, D, Kosiak, B, Dupree, J, Clemens, JQ. Pay for performance: rationale and potential implications for urology. J Urol, 178(2), 402-8, 2007

Graff, JN, Mori, M, Li, H, Garzotto, M, Penson, D, Potosky, AL, Beer, TM. Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study. J Urol, 177(4), 1307-12, 2007

Ramsey, SD, Zeliadt, SB, Hall, IJ, Ekwueme, DU, Penson, DF. On the importance of race, socioeconomic status and comorbidity when evaluating quality of life in men with prostate cancer. J Urol, 177(6), 1992-9, 2007

Singer, EA, Penson, DF, Palapattu, GS. PSA screening and elderly men. JAMA, 297(9), 949; author reply 949-50, 2007

Stein, JP, Penson, DF, Cai, J, Miranda, G, Skinner, EC, Dunn, MA, Groshen, S, Lieskovsky, G, Skinner, DG. Radical cystectomy with extended lymphadenectomy: evaluating separate package versus en bloc submission for node positive bladder cancer. J Urol, 177(3), 876-81; discussion 881-2, 2007

Stein, JP, Penson, DF, Wu, SD, Skinner, DG. Pathological guidelines for orthotopic urinary diversion in women with bladder cancer: a review of the literature. J Urol, 178(3 Pt 1), 756-60, 2007

Zeliadt, SB, Etzioni, R, Ramsey, SD, Penson, DF, Potosky, AL. Trends in treatment costs for localized prostate cancer: the healthy screenee effect. Med Care, 45(2), 154-9, 2007

Zeliadt, SB, Penson, DF. Pharmacoeconomics of available treatment options for metastatic prostate cancer. Pharmacoeconomics, 25(4), 309-27, 2007

Black, PC, Penson, DF. Prostate cancer on the Internet--information or misinformation. J Urol, 175(5), 1836-42; discussion 1842, 2006

Latini, DM, Penson, DF, Wallace, KL, Lubeck, DP, Lue, TF. Clinical and psychosocial characteristics of men with erectile dysfunction: baseline data from ExCEED. J Sex Med, 3(6), 1059-67, 2006

Latini, DM, Penson, DF, Wallace, KL, Lubeck, DP, Lue, TF. Longitudinal differences in psychological outcomes for men with erectile dysfunction: results from ExCEED. J Sex Med, 3(6), 1068-76, 2006

Penson, D, Moul, J, Gandhi, S, Newling, D. Use of prostate-specific antigen in the follow-up of patients with localized prostate cancer: results of a nationwide survey of urologists. Urology, 68(1), 80-4, 2006

Sanderson, KM, Penson, DF, Cai, J, Groshen, S, Stein, JP, Lieskovsky, G, Skinner, DG. Salvage radical prostatectomy: quality of life outcomes and long-term oncological control of radiorecurrent prostate cancer. J Urol, 176(5), 2025-31; discussion 2031-2, 2006

Yang, CC, Porter, MP, Penson, DF. Comparison of the International Index of Erectile Function erectile domain scores and nocturnal penile tumescence and rigidity measurements: does one predict the other. BJU Int, 98(1), 105-9; discussion 109, 2006

Zeliadt, SB, Potosky, AL, Penson, DF, Etzioni, R. Survival benefit associated with adjuvant androgen deprivation therapy combined with radiotherapy for high- and low-risk patients with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys, 66(2), 395-402, 2006

Albertsen, PC, Hanley, JA, Barrows, GH, Penson, DF, Kowalczyk, PD, Sanders, MM, Fine, J. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst, 97(17), 1248-53, 2005

Penson, DF, McLerran, D, Feng, Z, Li, L, Albertsen, PC, Gilliland, FD, Hamilton, A, Hoffman, RM, Stephenson, RA, Potosky, AL, Stanford, JL. 5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study. J Urol, 173(5), 1701-5, 2005

Penson, DF, Ramsey, S, Veenstra, D, Clarke, L, Gandhi, S, Hirsch, M. The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer. J Urol, 174(2), 547-52; discussion 552, 2005

Porter, MP, Penson, DF. Health related quality of life after radical cystectomy and urinary diversion for bladder cancer: a systematic review and critical analysis of the literature. J Urol, 173(4), 1318-22, 2005

Ramsey, S, Veenstra, D, Clarke, L, Gandhi, S, Hirsch, M, Penson, D. Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide. Urology, 66(4), 835-9, 2005

Zeliadt, SB, Etzioni, RD, Penson, DF, Thompson, IM, Ramsey, SD. Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer. Am J Med, 118(8), 850-7, 2005

Albertsen, PC, Hanley, JA, Penson, DF, Fine, J. Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation. J Urol, 171(6 Pt 1), 2221-5, 2004

Inoue, LY, Etzioni, R, Slate, EH, Morrell, C, Penson, DF. Combining longitudinal studies of PSA. Biostatistics, 5(3), 483-500, 2004

Johnson, TK, Gilliland, FD, Hoffman, RM, Deapen, D, Penson, DF, Stanford, JL, Albertsen, PC, Hamilton, AS. Racial/Ethnic differences in functional outcomes in the 5 years after diagnosis of localized prostate cancer. J Clin Oncol, 22(20), 4193-201, 2004

Neuhouser, ML, Kristal, AR, Penson, DF. Steroid hormones and hormone-related genetic and lifestyle characteristics as risk factors for benign prostatic hyperplasia: review of epidemiologic literature. Urology, 64(2), 201-11, 2004

Penson, DF, Moul, JW, Evans, CP, Doyle, JJ, Gandhi, S, Lamerato, L. The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data. J Urol, 171(6 Pt 1), 2250-4, 2004

Potosky, AL, Davis, WW, Hoffman, RM, Stanford, JL, Stephenson, RA, Penson, DF, Harlan, LC. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst, 96(18), 1358-67, 2004

Rosenfeld, B, Roth, AJ, Gandhi, S, Penson, D. Differences in health-related quality of life of prostate cancer patients based on stage of cancer. Psychooncology, 13(11), 800-7, 2004

Zeliadt, SB, Potosky, AL, Etzioni, R, Ramsey, SD, Penson, DF. Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology, 64(6), 1171-6, 2004

Latini, DM, Penson, DF, Lubeck, DP, Wallace, KL, Henning, JM, Lue, TF. Longitudinal differences in disease specific quality of life in men with erectile dysfunction: results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction study. J Urol, 169(4), 1437-42, 2003

Penson, DF, Feng, Z, Kuniyuki, A, McClerran, D, Albertsen, PC, Deapen, D, Gilliland, F, Hoffman, R, Stephenson, RA, Potosky, AL, Stanford, JL. General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes study. J Clin Oncol, 21(6), 1147-54, 2003

Penson, DF, Latini, DM, Lubeck, DP, Wallace, K, Henning, JM, Lue, T. Is quality of life different for men with erectile dysfunction and prostate cancer compared to men with erectile dysfunction due to other causes? Results from the ExCEED data base. J Urol, 169(4), 1458-61, 2003

Penson, DF, Latini, DM, Lubeck, DP, Wallace, KL, Henning, JM, Lue, TF, , . Do impotent men with diabetes have more severe erectile dysfunction and worse quality of life than the general population of impotent patients? Results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction (ExCEED) database. Diabetes Care, 26(4), 1093-9, 2003

Plaskon, LA, Penson, DF, Vaughan, TL, Stanford, JL. Cigarette smoking and risk of prostate cancer in middle-aged men. Cancer Epidemiol Biomarkers Prev, 12(7), 604-9, 2003

Zeliadt, SB, Penson, DF, Albertsen, PC, Concato, J, Etzioni, RD. Race independently predicts prostate specific antigen testing frequency following a prostate carcinoma diagnosis. Cancer, 98(3), 496-503, 2003

Etzioni, R, Penson, DF, Legler, JM, di Tommaso, D, Boer, R, Gann, PH, Feuer, EJ. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst, 94(13), 981-90, 2002

Latini, DM, Penson, DF, Colwell, HH, Lubeck, DP, Mehta, SS, Henning, JM, Lue, TF. Psychological impact of erectile dysfunction: validation of a new health related quality of life measure for patients with erectile dysfunction. J Urol, 168(5), 2086-91, 2002

Penson, DF, Grossfeld, GD, Li, YP, Henning, JM, Lubeck, DP, Carroll, PR. How well does the Partin nomogram predict pathological stage after radical prostatectomy in a community based population? Results of the cancer of the prostate strategic urological research endeavor. J Urol, 167(4), 1653-7; discussion 1657-8, 2002

Penson, DF, Paltiel, AD, Krumholz, HM, Palter, S. The cost-effectiveness of treatment for varicocele related infertility. J Urol, 168(6), 2490-4, 2002

Penson, DF, Albertsen, PC, Nelson, PS, Barry, M, Stanford, JL. Determining cause of death in prostate cancer: are death certificates valid. J Natl Cancer Inst, 93(23), 1822-3, 2001

Penson, DF, Schonfeld, WH, Flanders, SC, Henke, CJ, Warolin, KL, Carroll, PR, Litwin, MS. Relationship of first-year costs of treating localized prostate cancer to initial choice of therapy and stage at diagnosis: results from the CAPSURE database. Urology, 57(3), 499-503, 2001

Penson, DF, Stoddard, ML, Pasta, DJ, Lubeck, DP, Flanders, SC, Litwin, MS. The association between socioeconomic status, health insurance coverage, and quality of life in men with prostate cancer. J Clin Epidemiol, 54(4), 350-8, 2001

Corman, JM, Penson, DF, Hur, K, Khuri, SF, Daley, J, Henderson, W, Krieger, JN. Comparison of complications after radical and partial nephrectomy: results from the National Veterans Administration Surgical Quality Improvement Program. BJU Int, 86(7), 782-9, 2000

Taneja, SS, Penson, DF, Epelbaum, A, Handler, T, Lepor, H. Does site specific labeling of sextant biopsy cores predict the site of extracapsular extension in radical prostatectomy surgical specimen. J Urol, 162(4), 1352-7; discussion 1357-8, 1999

Penson, DF, Litwin, MS, Lubeck, DP, Flanders, S, Pasta, DJ, Carroll, PR. Transitions in health-related quality of life during the first nine months after diagnosis with prostate cancer. Prostate Cancer Prostatic Dis, 1(3), 134-143, 1998

Penson, DF, Lugg, JA, Coyne, C, Sadeghi, F, Freedman, AL, Gonzalez-Cadavid, NF, Rajfer, J. Effect of cryptorchidism on testicular histology in a naturally cryptorchid animal model. J Urol, 158(5), 1978-82, 1997

Penson, DF, Ng, C, Rajfer, J, Gonzalez-Cadavid, NF. Adrenal control of erectile function and nitric oxide synthase in the rat penis. Endocrinology, 138(9), 3925-32, 1997

Lugg, JA, Penson, DF, Sadeghi, F, Petrie, B, Freedman, AL, Gonzalez-Cadavid, NF, Hikim, AS, Rajfer, J. Prevention of seminiferous tubular atrophy in a naturally cryptorchid rat model by early surgical intervention. J Androl, 17(6), 726-32, 1996


Postdoctoral Position Available
N/A

Postdoctoral Position Details
N/A

Updated Date
07/17/2013